Olema Pharmaceuticals Stock Market Value
| OLMA Stock | USD 26.06 1.49 6.06% |
| Symbol | Olema |
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. Anticipated expansion of Olema directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Olema Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Olema Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Olema's balance sheet. Smart investors calculate Olema Pharmaceuticals' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Olema Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Olema Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Olema Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Olema Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Olema Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Olema Pharmaceuticals.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Olema Pharmaceuticals on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Olema Pharmaceuticals or generate 0.0% return on investment in Olema Pharmaceuticals over 90 days. Olema Pharmaceuticals is related to or competes with Ventyx Biosciences, Corvus Pharmaceuticals, Absci Corp, Regenxbio, Gossamer Bio, Prothena Plc, and Verastem. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and comm... More
Olema Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Olema Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Olema Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.03 | |||
| Information Ratio | 0.1454 | |||
| Maximum Drawdown | 145.73 | |||
| Value At Risk | (5.86) | |||
| Potential Upside | 9.82 |
Olema Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Olema Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Olema Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Olema Pharmaceuticals historical prices to predict the future Olema Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1176 | |||
| Jensen Alpha | 2.88 | |||
| Total Risk Alpha | 1.4 | |||
| Sortino Ratio | 0.6531 | |||
| Treynor Ratio | (0.69) |
Olema Pharmaceuticals January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1176 | |||
| Market Risk Adjusted Performance | (0.68) | |||
| Mean Deviation | 6.63 | |||
| Semi Deviation | 3.1 | |||
| Downside Deviation | 4.03 | |||
| Coefficient Of Variation | 672.1 | |||
| Standard Deviation | 18.09 | |||
| Variance | 327.43 | |||
| Information Ratio | 0.1454 | |||
| Jensen Alpha | 2.88 | |||
| Total Risk Alpha | 1.4 | |||
| Sortino Ratio | 0.6531 | |||
| Treynor Ratio | (0.69) | |||
| Maximum Drawdown | 145.73 | |||
| Value At Risk | (5.86) | |||
| Potential Upside | 9.82 | |||
| Downside Variance | 16.23 | |||
| Semi Variance | 9.59 | |||
| Expected Short fall | (9.17) | |||
| Skewness | 6.93 | |||
| Kurtosis | 51.76 |
Olema Pharmaceuticals Backtested Returns
Olema Pharmaceuticals is relatively risky given 3 months investment horizon. Olema Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of 0.15, which implies the firm had a 0.15 % return per unit of risk over the last 3 months. We have collected data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 2.69% are justified by taking the suggested risk. Use Olema Pharmaceuticals Coefficient Of Variation of 672.1, semi deviation of 3.1, and Risk Adjusted Performance of 0.1176 to evaluate company specific risk that cannot be diversified away. Olema Pharmaceuticals holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of -3.87, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Olema Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Olema Pharmaceuticals is expected to outperform it. Use Olema Pharmaceuticals standard deviation, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance , to analyze future returns on Olema Pharmaceuticals.
Auto-correlation | -0.38 |
Poor reverse predictability
Olema Pharmaceuticals has poor reverse predictability. Overlapping area represents the amount of predictability between Olema Pharmaceuticals time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Olema Pharmaceuticals price movement. The serial correlation of -0.38 indicates that just about 38.0% of current Olema Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | -0.54 | |
| Residual Average | 0.0 | |
| Price Variance | 7.24 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out Olema Pharmaceuticals Correlation, Olema Pharmaceuticals Volatility and Olema Pharmaceuticals Performance module to complement your research on Olema Pharmaceuticals. For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Olema Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.